video

Supercharging a New FDA: Marty Makary on Science, Power & Patients

All-In Podcast
Jan 15, 2026
1h 29m
122,996 views

TLDR

FDA Commissioner Marty Makary discusses his mission to modernize the FDA by reducing regulatory red tape, accelerating drug approval timelines, and rebuilding public trust through scientific transparency. He emphasizes the need for the US to outpace China in biotechnology and advocates for a "common sense" approach to nutrition and medicine.

General Summary #

In this interview from the All-In Podcast, host David Sacks sits down with FDA Commissioner Marty Makary during the JP Morgan Healthcare Conference in San Francisco 0:00. Makary, a former Johns Hopkins surgeon and professor, outlines a massive restructuring of the FDA aimed at moving the agency away from "medical dogma" and "paternalism" toward a model of transparency, speed, and competitiveness 3:34.

The conversation covers the agency's efforts to accelerate drug development, such as reducing the requirement for two pivotal clinical trials down to one 14:15, and the implementation of "Most Favored Nation" pricing to lower drug costs 1:00:30. Makary also addresses the geopolitical necessity of maintaining US leadership in biotechnology against rising competition from China 7:48.

Beyond drug regulation, the discussion delves into significant shifts in public health guidance, including the overhaul of the American food pyramid to prioritize protein over refined carbohydrates 35:06 and the review of the US vaccine schedule to rebuild trust among parents 52:46. Ultimately, Makary argues that the FDA must move at the "speed that patients demand" rather than at a sluggish "government speed" 1:28:58.

Key Topics #

FDA Modernization: Implementing 42 major reforms to improve agency efficiency and transparency 4:39.
Biotech Competitiveness: The race between the US and China to lead in life sciences and the impact of regulatory red tape 7:48.
Drug Development Reform: Accelerating timelines for drug approvals and reducing the cost of biosimilars 1:01:12.
Nutritional Science Overhaul: Moving away from the "carbohydrate-heavy" diet toward a focus on protein and "real food" 35:06.
Vaccine Schedule Review: Assessing the US vaccine schedule to reduce the number of doses and restore public confidence 52:46.
Drug Pricing and Access: Using "Most Favored Nation" pricing and transitioning more medications to over-the-counter (OTC) availability 1:00:30.

Who #

Marty Makary: Commissioner of the FDA, former Johns Hopkins surgeon, and author on healthcare transparency 0:43.
David Sacks: Interviewer and host of the All-In Podcast.
Jay Bhattacharya: Mentioned as a collaborator with Makary in challenging COVID-era school closures 2:49.
Dr. Oz: Mentioned in the context of leadership at CMS and drug pricing initiatives 1:00:30.

What #

FDA Structural Reforms: A massive restructuring of the FDA's seven centers to centralize services and eliminate "siloed" communication 31:30.
Clinical Trial Simplification: A new policy moving from a default requirement of two pivotal trials to one pivotal trial for certain drugs to save costs and time 14:15.
Food Guidance Changes: The flipping of the food pyramid to emphasize protein and reduce the reliance on refined carbohydrates and added sugars 35:06.
Vaccine Schedule Reduction: A strategic review to reduce the recommended number of vaccine doses from an international outlier of 72 down to a core list of approximately 38 52:46.
Drug Pricing Policy: Implementing "Most Favored Nation" status to ensure the US receives the best prices available in the developed world 1:00:30.

When #

Post-COVID Era: The context for the current focus on rebuilding public trust in health institutions 3:11.
2025-2026: The period during which the discussed FDA reforms and new dietary guidelines are being actively implemented [The context of the video/transcript].

Where #

San Francisco: The location of the interview, coinciding with the JP Morgan Healthcare Conference 0:00.
Johns Hopkins: Makary's former professional home and site of his clinical practice 1:04.
United States vs. China/Australia: The global landscape of biotech innovation and the competitive pressure on US research 7:48.

Why #

Global Competition: To prevent China and Australia from outperforming the US in biotechnology due to superior efficiency and less red tape 9:16.
Restoring Public Trust: To combat the loss of confidence in health institutions caused by "medical dogma" and pandemic-era mandates 3:11.
Innovation and Speed: To reduce the 10-12 year timeline for bringing new drugs to market 4:59.
Health Improvement: To address the rise in chronic diseases, such as diabetes and obesity, driven by nutritional and environmental factors 34:02.

Speaker Summaries #

Marty Makary: Serves as the primary subject, detailing his transition from academia to the FDA. He advocates for "common sense" science, the elimination of unnecessary regulatory red tape, and a shift away from paternalistic medical practices. He highlights specific successes in drug approvals, dietary changes, and the need for the US to compete with China.
David Sacks: Acts as the interviewer, framing the discussion around national security, economic competitiveness, and the practical impacts of FDA decisions on patients and the biotech industry.

Discussion Topics #

The US vs. China Biotech Race: The danger of US innovation being "clocked" by overseas competitors due to excessive red tape and inefficient hospital IRB processes 8:09.
The Death of Medical Paternalism: The debate over whether the FDA should allow more patient autonomy in things like vaccine schedules and over-the-counter drug access 53:47.
The Nutrition/Chronic Disease Link: The debate over the "science" of saturated fat versus the reality of insulin resistance and the rise of refined carbohydrates 34:02.
The Role of AI: The potential for AI to accelerate drug applications and assist in continuous monitoring, provided there is regulatory "predictability" 11:24.

Action Items #

Drug Approval Speed: The FDA intends to reduce the time for notification of application completeness from 60 days to one day using AI 11:03.
Drug Pricing: Implementing "Most Favored Nation" pricing to lower costs for Americans 1:00:30.
Clinical Trial Reform: Moving toward a single-pivotal trial standard to accelerate the pharmaceutical pipeline 14:15.

Comments Summary #

Overall Sentiment

The overall sentiment is overwhelmingly positive and enthusiastic. Viewers expressed great excitement for the new direction of the FDA under Dr. Makary, praised David Friedberg's deep-dive interviewing style, and shared a sense of optimism regarding science-led, transparent leadership in healthcare and nutrition.

Recurring Themes

Praise for David Friedberg's thorough research and interviewing skills
Support for Dr. Marty Makary’s leadership and "common sense" approach
Optimism regarding FDA regulatory reform and more efficient drug approvals
The importance of nutrition, "food as medicine," and preventive health
Distrust of previous political and corporate influences on medical science

Notable Comments

"I’m really enjoying these one-on-one talks you’ve been doing David. I’ve already watched a few and they’re great." — @thefifthelement1, 256 likes

"Politics and monied interests have displaced medical science for far too long. A welcome change and a great interview." — @juliusbrown101, 144 likes

"I am a cancer free human due to CAR-T... I am so Thankful for the Dr's, Researchers and medical personnel who brought this technology into existence." — @JPBrowning53, 77 likes

"As a Stage IVB cancer survivor, I am astonished at how little conversation there has been about the preventative steps that matter most..." — @davidluria3877, 38 likes

Questions Raised

Can we have a Jay Bhattacharya interview next?
How do we get more of this [type of conversation]?

Export as YouTube chapters Paste into a video description for scrubber markers, or a comment as a topic index.

00:00 In this interview from the All-In Podcast, host David Sacks sits down with FDA Commissioner Marty Makary during the JP Morgan Healthcare Conference in San Francisco . Makary, a former Johns Hopkins surgeon and professor, outlines a massive restructuring of the FDA aimed at moving the agency away from "medical dogma" and "paternalism" toward a model of transparency, speed, and competitiveness
00:43 Marty Makary : Commissioner of the FDA, former Johns Hopkins surgeon, and author on healthcare transparency
01:04 Johns Hopkins : Makary's former professional home and site of his clinical practice
02:49 Jay Bhattacharya : Mentioned as a collaborator with Makary in challenging COVID-era school closures
03:11 Post-COVID Era : The context for the current focus on rebuilding public trust in health institutions
03:34 In this interview from the All-In Podcast, host David Sacks sits down with FDA Commissioner Marty Makary during the JP Morgan Healthcare Conference in San Francisco . Makary, a former Johns Hopkins surgeon and professor, outlines a massive restructuring of the FDA aimed at moving the agency away from "medical dogma" and "paternalism" toward a model of transparency, speed, and competitiveness
04:39 FDA Modernization : Implementing 42 major reforms to improve agency efficiency and transparency
04:59 Innovation and Speed : To reduce the 10-12 year timeline for bringing new drugs to market
07:48 The conversation covers the agency's efforts to accelerate drug development, such as reducing the requirement for two pivotal clinical trials down to one , and the implementation of "Most Favored Nation" pricing to lower drug costs . Makary also addresses the geopolitical necessity of maintaining US leadership in biotechnology against rising competition from China
08:09 The US vs. China Biotech Race : The danger of US innovation being "clocked" by overseas competitors due to excessive red tape and inefficient hospital IRB processes
09:16 Global Competition : To prevent China and Australia from outperforming the US in biotechnology due to superior efficiency and less red tape
11:03 Drug Approval Speed : The FDA intends to reduce the time for notification of application completeness from 60 days to one day using AI
11:24 The Role of AI : The potential for AI to accelerate drug applications and assist in continuous monitoring, provided there is regulatory "predictability"
14:15 The conversation covers the agency's efforts to accelerate drug development, such as reducing the requirement for two pivotal clinical trials down to one , and the implementation of "Most Favored Nation" pricing to lower drug costs . Makary also addresses the geopolitical necessity of maintaining US leadership in biotechnology against rising competition from China
31:30 FDA Structural Reforms : A massive restructuring of the FDA's seven centers to centralize services and eliminate "siloed" communication
34:02 Health Improvement : To address the rise in chronic diseases, such as diabetes and obesity, driven by nutritional and environmental factors
35:06 Beyond drug regulation, the discussion delves into significant shifts in public health guidance, including the overhaul of the American food pyramid to prioritize protein over refined carbohydrates and the review of the US vaccine schedule to rebuild trust among parents . Ultimately, Makary argues that the FDA must move at the "speed that patients demand" rather than at a sluggish "government speed"
52:46 Beyond drug regulation, the discussion delves into significant shifts in public health guidance, including the overhaul of the American food pyramid to prioritize protein over refined carbohydrates and the review of the US vaccine schedule to rebuild trust among parents . Ultimately, Makary argues that the FDA must move at the "speed that patients demand" rather than at a sluggish "government speed"
53:47 The Death of Medical Paternalism : The debate over whether the FDA should allow more patient autonomy in things like vaccine schedules and over-the-counter drug access
1:00:30 The conversation covers the agency's efforts to accelerate drug development, such as reducing the requirement for two pivotal clinical trials down to one , and the implementation of "Most Favored Nation" pricing to lower drug costs . Makary also addresses the geopolitical necessity of maintaining US leadership in biotechnology against rising competition from China
1:01:12 Drug Development Reform : Accelerating timelines for drug approvals and reducing the cost of biosimilars
1:28:58 Beyond drug regulation, the discussion delves into significant shifts in public health guidance, including the overhaul of the American food pyramid to prioritize protein over refined carbohydrates and the review of the US vaccine schedule to rebuild trust among parents . Ultimately, Makary argues that the FDA must move at the "speed that patients demand" rather than at a sluggish "government speed"